News
-
-
-
-
PRESS RELEASE
FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticorelin on track for Phase 3
Curatis Holding AG receives positive outcome confirmation from FDA meeting regarding corticorelin's Phase 3 development plan for patients with PTBE secondary to solid tumor brain metastases -
-
PRESS RELEASE
Curatis: Double-digit growth in core business and development milestone achieved for C-PTBE-01
Curatis Holding AG reports double-digit revenue growth in H1 2025, signing a significant partnership with Phoenix Labs for C-PTBE-01. Financials show a loss due to increased development expenses for corticorelin -
-
PRESS RELEASE
Curatis expands distribution business with Phoenix Labs with up to CHF 5m additional annual revenues
Curatis Holding AG announces new distribution contract with Phoenix Labs (Ireland) for four products in Switzerland, expecting up to CHF 5 million additional annual revenues from October 2025 -
-